Bristol-Myers is surfing for first place on the $33B PD-1 tsunami: analysts

There's a reason immuno-oncology is among the hottest fields in biopharma today--and that's the $20 billion or so in 2022 sales that many analysts estimate. No wonder Bristol-Myers Squibb ($BMY), Merck ($MRK), AstraZeneca ($AZN) and Roche ($RHHBY) are speeding ahead with their research in the field, with Sanofi ($SNY), Novartis ($NVS) and Pfizer ($PFE) racing to catch up.

But according to Morningstar, those sales estimates are low--way low.

In fact, according to a new report from the investment firm, the market for PD-1 and PD-L1 drugs is billions of dollars richer than many analysts believe. That's good news for every drugmaker in the field. But the best news from Morningstar comes for Bristol-Myers. More

Suggested Articles

BMS' Opdivo and Yervoy only just won their first approval in previously untreated metastatic NSCLC, but the pair is already making it two.

Takeda’s Alunbrig has arrived in previously untreated, ALK-positive NSCLC. But there’s plenty of competition waiting to greet it at the door.

Sanofi and Regeneron's blockbuster Dupixent is eyeing an approval in eosinophilic esophagitis after cutting patients' difficulty breathing.